BVS

9.01

3.10% -0.27

Handel nachbörslich: 9.02 0.010 +0.11%

Bioventus Inc (BVS)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$9.28

Offen:

$9.33

24-Stunden-Volumen:

706.35K

Relative Volume:

1.48

Marktkapitalisierung:

$610.41M

Einnahmen:

$568.09M

Nettoeinkommen (Verlust:

$27.27M

KGV:

27.50

EPS:

0.3276

Netto-Cashflow:

$71.41M

1W Leistung:

-15.65%

1M Leistung:

-10.88%

6M Leistung:

+17.54%

1J Leistung:

+37.70%

1-Tages-Spanne:

$8.90

$9.575

1-Wochen-Bereich:

$8.90

$11.00

52-Wochen-Spanne:

$5.81

$11.25

Bioventus Inc Stock (BVS) Company Profile

Firmenname

Bioventus Inc

Sektor

Healthcare (1113)

Branche

Medical Devices (143)

Telefon

(919) 474-6700

Adresse

4721 EMPEROR BOULEVARD, SUITE 100, DURHAM

Mitarbeiter

940

Twitter

Nächster Verdiensttermin

2026-05-06

Neueste SEC-Einreichungen

BVS's Discussions on Twitter

Compare BVS vs ABT, SYK, MDT, BSX, EW

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
BVS Bioventus Inc	9.01	628.70M	568.09M	27.27M	71.41M	0.3276
ABT Abbott Laboratories	86.66	152.25B	45.13B	6.28B	7.38B	3.5895
SYK Stryker Corp	312.95	121.33B	25.27B	3.34B	4.57B	8.6334
MDT Medtronic Plc	77.59	100.91B	35.48B	4.64B	5.41B	3.582
BSX Boston Scientific Corp	57.66	85.88B	20.62B	3.56B	3.48B	2.3847
EW Edwards Lifesciences Corp	87.56	49.39B	6.30B	1.07B	1.09B	1.8406

Bioventus Inc Stock (BVS) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-03-27	Eingeleitet	CJS Securities	Market Outperform
2026-02-09	Eingeleitet	Barrington Research	Outperform
2025-07-07	Eingeleitet	Cantor Fitzgerald	Overweight
2024-12-17	Hochstufung	JP Morgan	Underweight → Neutral
2023-12-07	Hochstufung	Canaccord Genuity	Hold → Buy
2023-08-09	Hochstufung	Craig Hallum	Hold → Buy
2022-11-22	Herabstufung	Craig Hallum	Buy → Hold
2022-11-09	Herabstufung	Canaccord Genuity	Buy → Hold
2022-11-09	Herabstufung	JP Morgan	Overweight → Underweight
2022-03-15	Eingeleitet	Craig Hallum	Buy
2021-11-15	Fortgesetzt	Morgan Stanley	Overweight
2021-11-10	Fortgesetzt	JP Morgan	Overweight
2021-07-01	Herabstufung	Goldman	Buy → Neutral
2021-03-08	Eingeleitet	Canaccord Genuity	Buy
2021-03-08	Eingeleitet	Goldman	Buy
2021-03-08	Eingeleitet	JP Morgan	Overweight
2021-03-08	Eingeleitet	Morgan Stanley	Overweight

Alle ansehen

Bioventus Inc Aktie (BVS) Neueste Nachrichten

May 24, 2026

Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing It - Benzinga

May 22, 2026

Bioventus Is Maintained at Outperform by Barrington Research - Moomoo

May 22, 2026

Bioventus Inc. Files Form 8-K: Corporate Details, Stock Information, and SEC Compliance for May 2026 - Minichart

May 22, 2026

May 21, 2026

FDA reclassifies Bioventus bone growth stimulator; company maintains 2026 outlook - Investing.com UK

May 21, 2026

FDA reclassifies Bioventus bone growth stimulator; company maintains 2026 outlook By Investing.com - Investing.com South Africa

May 21, 2026

Bioventus Inc stated in a filing with the SEC that expected adjustments to reimbursement policies related to the Exogen bone healing system are not anticipated to have a material impact on the company’s financial position for fiscal year 2026. - Bitget

May 21, 2026

According to documents submitted to the U.S. Securities and Exchange Commission, SEACOR Marine Holdings Inc. expects its newly built platform supply vessels to be delivered successively in the fourth quarter of 2026 and the first quarter of 2027. - Bitget

May 21, 2026

GE Vernova Inc. announces the acquisition of Robotech Automation to accelerate advancements in its robotics and automation capabilities. - Bitget

May 21, 2026

According to documents submitted to the U.S. Securities and Exchange Commission, the U.S. Food and Drug Administration completed the reclassification of Bioventus Inc.'s Exogen ultrasound bone healing system on April 16, 2026. - Bitget

May 21, 2026

FDA reclassifies bone growth stimulators; Bioventus says 2026 guidance unchanged - TradingView

May 21, 2026

CMS reimbursement shifts leave Bioventus (NASDAQ: BVS) 2026 guidance intact - Stock Titan

May 21, 2026

Is Bioventus (BVS) Stock Undervalued Right Now? - Yahoo Finance

May 21, 2026

May 18, 2026

Are Medical Stocks Lagging Bioventus (BVS) This Year? - Yahoo Finance

May 18, 2026

May 17, 2026

(BVS) Volatility Zones as Tactical Triggers - Stock Traders Daily

May 17, 2026

May 15, 2026

Bioventus (BVS) Q1 2026 Earnings: EPS $0.15 Beats EstimatesHot Community Stocks - Newser

May 15, 2026

Statutory Profit Doesn't Reflect How Good Bioventus' (NASDAQ:BVS) Earnings Are - Sahm

May 15, 2026

May 14, 2026

Bioventus' (NASDAQ:BVS) Solid Earnings Are Supported By Other Strong Factors - Yahoo Finance

May 14, 2026

May 09, 2026

Bioventus (BVS) Q1 2026 Earnings Transcript - AOL.com

May 09, 2026

May 08, 2026

Wall Street analysts see a 38.97% upside in Bioventus (BVS): Can the stock really move this high? - MSN

May 08, 2026

Wall Street Analysts See a 38.97% Upside in Bioventus (BVS): Can the Stock Really Move This High? - Yahoo Finance

May 08, 2026